Last reviewed · How we verify

AB Science — Portfolio Competitive Intelligence Brief

AB Science pipeline: 0 marketed, 0 filed, 3 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Masitinib (4.5) Masitinib (4.5) phase 3 Tyrosine kinase inhibitor c-KIT, PDGFR, Lyn Oncology, Immunology, Neurology
Masitinib (6.0) Masitinib (6.0) phase 3 Tyrosine kinase inhibitor c-Kit, PDGF receptor, Lyn kinase Neurology, Immunology, Oncology
Riluzole (100 mg) Riluzole (100 mg) phase 3 Glutamate antagonist / Neuroprotective agent Glutamate release (presynaptic); voltage-gated sodium channels Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 2 shared drug classes
  2. Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes
  3. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
  4. Amorphical Ltd. · 1 shared drug class
  5. Angion Biomedica Corp · 1 shared drug class
  6. Angitia Incorporated Limited · 1 shared drug class
  7. Applied Biology, Inc. · 1 shared drug class
  8. Akeso · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for AB Science:

Cite this brief

Drug Landscape (2026). AB Science — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ab-science. Accessed 2026-05-13.

Related